Can a 7.5 mg mirtazapine tablet be safely split in half?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can You Split a 7.5 mg Mirtazapine Tablet in Half?

No, you should not split a 7.5 mg mirtazapine tablet in half. Mirtazapine is not commercially available in a 7.5 mg tablet formulation according to FDA labeling—the available strengths are 15 mg (scored), 30 mg (scored), and 45 mg (unscored) 1. If you have been taking what you believe is a 7.5 mg dose, you are likely already splitting a 15 mg scored tablet in half, which is acceptable practice.

Understanding Mirtazapine Formulations and Splitting

Available Tablet Strengths

The FDA-approved mirtazapine tablets come in three strengths 1:

  • 15 mg tablets: Scored (can be split)
  • 30 mg tablets: Scored (can be split)
  • 45 mg tablets: Unscored (should NOT be split)

The presence of a score line on the 15 mg and 30 mg tablets indicates the manufacturer designed them to be divided if needed.

Why Splitting Your Current Dose Further Is Problematic

If you're taking 7.5 mg (half of a 15 mg tablet) and want to reduce to 3.75 mg (quarter of a 15 mg tablet), this creates several concerns:

Dose accuracy issues: Research demonstrates that tablet splitting can result in significant weight and content variation. In one study of mirtazapine 30 mg tablets, splitting produced acceptable uniformity 2. However, splitting already-split tablets (creating quarters) dramatically increases the risk of unequal dosing, with fragments potentially falling outside acceptable pharmaceutical standards.

Fragment loss: The splitting process causes powder loss, particularly problematic when creating very small doses. Studies show mean weight loss of up to 1.5% during splitting, with some medications showing higher powdering loss 2. When you're working with an already-small 7.5 mg dose, further splitting magnifies this problem.

Clinical implications: Mirtazapine has dose-dependent effects. At lower doses (7.5-15 mg), its primary action is histamine H1 antagonism, producing sedation 1. Inconsistent dosing from imprecise splitting could lead to unpredictable sedative effects and potentially compromise therapeutic benefit.

What You Should Do Instead

If you need to reduce your dose below 7.5 mg:

  • Consult your prescriber about whether dose reduction is appropriate
  • Consider liquid formulations if available, which allow more precise low-dose titration
  • Discuss whether the dose reduction is clinically necessary, as mirtazapine's therapeutic range for depression is typically 15-45 mg daily 3, 4

If you're currently splitting a 15 mg tablet to get 7.5 mg:

  • This is acceptable practice since the 15 mg tablet is scored for splitting 1
  • Use a proper tablet splitter rather than a knife for more consistent results 2
  • Take the medication at the same time daily to maintain steady-state levels

Important Caveats

Therapeutic considerations: The guidelines note that mirtazapine at low doses (such as 7.5 mg) is used primarily for sedation and sleep, not for antidepressant effects 3, 5. If you're using it for depression, doses below 15 mg are generally subtherapeutic. The typical starting dose for depression is 15 mg at bedtime, with therapeutic doses ranging from 15-45 mg daily 4.

Patient-specific factors: Elderly patients and those with hepatic or renal impairment may require lower doses due to reduced clearance 1. However, even in these populations, dose adjustments should be made by using the appropriate tablet strength rather than creating very small fragments through multiple splits.

References

Guideline

clinical guideline for the evaluation and management of chronic insomnia in adults.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

Guideline

palliative care version 1.2016.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.